As out-of-pocket costs go up for drugs for the neurologic disorders Alzheimer's disease, peripheral neuropathy and Parkinson's disease, people are less likely to take the drugs as often as their doctors prescribed, according to a study funded by the American Academy of Neurology and published in the Feb. 19, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
The top contributor to familial Parkinson's disease is mutations in leucine-rich repeat kinase 2 (LRRK2), whose large and difficult structure has finally been solved, paving the way for targeted therapies.
A promising molecule has offered hope for a new treatment that could stop or slow Parkinson's, something no treatment can currently do.
Astrocytes are neural cells with many important functions in the nervous system. The inflammation of these cells occurs in brain infections and neurodegenerative disorders, a process called astrogliosis. Aware of this fundamental process for the prevention of diseases and improvement of current treatments, a team led by researchers at the D'Or Institute for Research and Education (IDOR) and other five Brazilian Federal Universities published one of the first studies to categorically observe this inflammatory reaction in human astrocytes created in the laboratory.
Parkinson's disease is a long-term (chronic) neurological condition that affects the way the brain co-ordinates body movements like walking and talking, as well as cognitive abilities. There is currently no cure for the disease, but researchers at Trinity have recently published findings of a study which may lead to better treatments for this debilitating illness. The paper has been published in the international Cell Press journal Structure.
Disease-prompting bundles of proteins found within cells are cleared by unexpected processes. That knowledge could lead to ALS therapeutic solutions.
In order to provide the best medical care for newly diagnosed Parkinson's disease (PD) patients, a method of predicting their cognitive and motor progression, beyond using purely clinical parameters, would have major implications for their management.
To better understand the relationship between physical activity and Parkinson's Disease (PD) investigators in Sweden analyzed medical records of nearly 200,000 long-distance skiers who took part in the Vasaloppet cross-country ski race. They established that a physically active lifestyle is associated with close to a 30% reduced risk for PD, which might be explained by a motor reserve among the physically active, however, this dissipates as individuals age.
A team of engineers from University of Arizona, George Washington University and Northwestern University have created an ultra-small, wireless, battery-free device that uses light to record individual neurons so neuroscientists can see how the brain is working.
This randomized clinical trial that included 210 patients with Parkinson's disease and related disorders and 175 caregivers examined whether outpatient palliative care was associated with better patient or caregiver outcomes compared with standard care.